the aid library

LIST OPTIONS

Filter

5065

Sort by:

Direction:

Download (355)

View PDF (502)

Bangladesh Maternal Health Services and Maternal Mortality Survey 2001

National Institute of Population Research and Training (NIPORT), ORC Macro, Johns Hopkins University and ICDDR,B (2003) C1

Download (143)

View PDF (208)

Health Facility and Health Worker Baseline Assessment for Reproductive, Maternal, Neonatal, Child Health and Nutrition Services

Millennium Development Goal Acceleration Initiative Government of Zambia (2015) CC

Download (180)

View PDF (327)

Promoting recovery in mental health and related services: handbook for personal use and teaching WHO QualityRights training to act, unite and empower for mental health (P I L O T V E R S I O N)

World Health Organization WHO (2017) C_WHO

This handbook and teaching guide on recovery has been designed to complement the QualityRights training module on Promoting Recovery in Mental Health and Related Services. The handbook and teaching guide covers much of the same material, but also contains additional text and exercises. It can be giv... more

Download (188)

View PDF (291)

Punjab Province Report: Nutrition Political Economy, Pakistan

Zaidi, Shehla; Bhutta, Zulfiqar et al. Institute of Development Studies, Aga Khan University (2015) C1

In this report a nutrition governance framework was applied to research and analyse the provincial experience with nutrition policy in Pakistan, looking both at chronic and acute malnutrition. Twenty-one in-depth interviews with key stakeholders were also conducted along with a review of published a... more

Download (405)

View PDF (556)

Maternal and Child Health in Namibia

World Health Organization (WHO) (2009) C_WHO

2nd Edition

Download (639)

View PDF (896)

Improving the quality of care for mothers and newborns in health facilities: facilitator's manual. Version 02.

World Health Organization (WHO), Regional Office for South-East Asia (2017) C_WHO

WHO-SEARO in partnership with WHOCC AIIMS, UNICEF, UNFPA and USAID has prepared a training package for building capacity of healthcare teams in health facilities for continous quality improvement of maternal and newborn healthcare. The focus is on the care of mothers and newborns at the time of chil... more

Download (389)

View PDF (638)

Defining competent maternal and newborn health professionals

World Health Organization WHO; UNFPA; UNICEF; et al. (2018) C_WHO

Background document to the 2018 joint statement by WHO, UNFPA, UNICEF, ICM, ICN, FIGO and IPA: definition of skilled health personnel providing care during childbirth

Download (236)

View PDF (350)

A Decade of Tracking Progress for Maternal, Newborn and Child Survival: The 2015 Report

United Nations Children’s Fund (UNICEF), World Health Organization (WHO) (2015)

Download (133)

View PDF (170)

Review of Evidence on Antimicrobial Resistance and Animal Agriculture in Developing Countries

Grace, D. International Livestock Research Institute (ILRI) (2015) C2

This short paper aims to identify key evidence gaps in our knowledge of livestock- and fisheries-linked antimicrobial resistance in the developing world, and to document on-going or planned research initiatives on this topic by key stakeholders. The antimicrobial resistant (AMR) infections in anima... more

Download (319)

View PDF (240)

Wound Care Protocol

Medicins Sans Frontieres MSF (2018) C2

Wound care is a regular component of the package of care we offer in the majority of our health care facilities and represents a high volume of activities. The current practices in MSF projects are often based on the habits of each individual supervisor, the wound care material we off... more

Download (286)

View PDF (240)

WHO recommendations on maternal and newborn care for a positive postnatal experience. Presentation
recommended

World Health Organization WHO (2022) CC

This guideline aims to improve the quality of essential, routine postnatal care for women and newborns with the ultimate goal of improving maternal and newborn health and well-being. It recognizes a “positive postnatal experience” as a significant end point for all women giving birth and their n... more

Download (197)

View PDF (249)

WHO recommendations on maternal and newborn care for a positive postnatal experience
recommended

World Health Organization WHO (2022) CC

Download (121)

View PDF (609)

Ethiopia - Multi-Sectorial Cholera Elimination Plan 2022 - 2028

Government of Ethiopia (2023) CC

Cholera which disproportionally impacts poor countries and the most vulnerable continues to affect at least 47 countries across the globe, resulting in an estimated 1.3 – 4 million cases, and 21,000 - 143,000 deaths per year worldwide. In Ethiopia, despite major improvements seen in the increasing... more

Download (113)

View PDF (132)

WHO Timor-Leste Country Cooperation Strategy: 2021-2025

World Health Organisation (WHO) (2023) C_WHO

In the last decade, Timor-Leste has made remarkable progress in strengthening its health system and improving the health status of its population. This has resulted in an increased life expectancy, and the achievement of Millennium Development Goals such as a reduction in infant and under-five morta... more

Download (92)

View PDF (149)

Countdown to 2015: an analysis of donor funding for prenatal and neonatal health, 2003–2013

Pitt, C.; C. Grollman; M. Martínez-Álvarez et al. BMJ Global Health (2017) C1

Background: In 2015, 5.3 million babies died in the third trimester of pregnancy and first month following birth. Progress in reducing neonatal mortality and stillbirth rates has lagged behind the substantial progress in reducing postneonatal and maternal mortality rates. The benefits to prenatal an... more

Download (172)

View PDF (147)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (24)

View PDF (20)

The Treatment of Heart Failure with Reduced Ejection Fraction

Berliner, D.; Hänselmann, A.; Bauersachs, J. Deutsches Ärzteblatt International (2020) CC

Background Chronic congestive heart failure is a common condition that, if untreated, markedly impairs the quality of life and is associated with a high risk of recurrent hospitalization and death. Methods This review is based on articles retrieved by a selective search in PubMed, as well as on r... more

Download (26)

View PDF (20)

Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward

Minja, N.W.; Nakagaayi, D.; Aliku, T. et al. Frontiers in Cardiovascular Medicine (2022) CC

In 2015, the United Nations set important targets to reduce premature cardiovascular disease (CVD) deaths by 33% by 2030. Africa disproportionately bears the brunt of CVD burden and has one of the highest risks of dying from non-communicable diseases (NCDs) worldwide. There is currently an epide...miological transition on the continent, where NCDs is projected to outpace communicable diseases within the current decade. Unchecked increases in CVD risk factors have contributed to the growing burden of three major CVDs—hypertension, cardiomyopathies, and atherosclerotic diseasesleading to devastating rates of stroke and heart failure. The highest age standardized disability-adjusted life years (DALYs) due to hypertensive heart disease (HHD) were recorded in Africa. The contributory causes of heart failure are changing—whilst HHD and cardiomyopathies still dominate, ischemic heart disease is rapidly becoming a significant contributor, whilst rheumatic heart disease (RHD) has shown a gradual decline. In a continent where health systems are traditionally geared toward addressing communicable diseases, several gaps exist to adequately meet the growing demand imposed by CVDs. Among these, high-quality research to inform interventions, underfunded health systems with high out-of-pocket costs, limited accessibility and affordability of essential medicines, CVD preventive services, and skill shortages. Overall, the African continent progress toward a third reduction in premature mortality come 2030 is lagging behind. More can be done in the arena of effective policy implementation for risk factor reduction and CVD prevention, increasing health financing and focusing on strengthening primary health care services for prevention and treatment of CVDs, whilst ensuring availability and affordability of quality medicines. Further, investing in systematic country data collection and research outputs will improve the accuracy of the burden of disease data and inform policy adoption on interventions. This review summarizes the current CVD burden, important gaps in cardiovascular medicine in Africa, and further highlights priority areas where efforts could be intensified in the next decade with potential to improve the current rate of progress toward achieving a 33% reduction in CVD mortality. more

Download (3)

View PDF (2)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

WHO recommendations on maternal and newborn care for a positive postnatal experience. Presentation recommended

WHO recommendations on maternal and newborn care for a positive postnatal experience recommended

WHO recommendations on maternal and newborn care for a positive postnatal experience. Presentation
recommended

WHO recommendations on maternal and newborn care for a positive postnatal experience
recommended